KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Operating Leases (2019 - 2025)

Astrazeneca (AZN) has 3 years of Operating Leases data on record, last reported at $1.4 billion in Q4 2025.

  • For Q4 2025, Operating Leases rose 27.67% year-over-year to $1.4 billion; the TTM value through Dec 2025 reached $1.4 billion, up 27.67%, while the annual FY2025 figure was $1.4 billion, 27.67% up from the prior year.
  • Operating Leases reached $1.4 billion in Q4 2025 per AZN's latest filing, up from $1.1 billion in the prior quarter.
  • Across five years, Operating Leases topped out at $1.4 billion in Q4 2025 and bottomed at $857.0 million in Q4 2023.
  • Average Operating Leases over 3 years is $1.1 billion, with a median of $1.1 billion recorded in 2024.
  • Peak YoY movement for Operating Leases: increased 29.87% in 2024, then grew 27.67% in 2025.
  • A 3-year view of Operating Leases shows it stood at $857.0 million in 2023, then increased by 29.87% to $1.1 billion in 2024, then increased by 27.67% to $1.4 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $1.4 billion in Q4 2025, $1.1 billion in Q4 2024, and $857.0 million in Q4 2023.